Spontaneous regression of tumours. Possible cross reactivity of autoantibodies against carbonic anhydrase I.
Ján LakotaPublished in: Journal of cellular and molecular medicine (2023)
Spontaneous tumour regression in patients after high dose therapy and autologous stem cell transplantation or patients with standard therapy is accompanied with the presence of high titers autoantibodies against carbonic anhydrase I (CA I). The concomitant presence of aplastic anaemia-like syndrome in these patients points to parallel bone marrow suppression during this period. It seems that CA I, an 'obscure' enzyme, does not have any significant physiological role in humans. One possible explanation points to the fact that autoantibodies against CA I may target another antigen(s) which is(are) important in tumour growth as well as in normal haematopoiesis. One of the candidates for such a target is the DNA polymerase theta.
Keyphrases
- high dose
- stem cell transplantation
- end stage renal disease
- bone marrow
- chronic kidney disease
- ejection fraction
- newly diagnosed
- systemic lupus erythematosus
- peritoneal dialysis
- low dose
- mesenchymal stem cells
- prognostic factors
- stem cells
- acute myeloid leukemia
- cell therapy
- patient reported outcomes
- smoking cessation